The genomic region of the miR-142 gene (containing miR-142-5p and miR-142-3p) (all patients), miR-632 (CN-AML and MDS patients) and miR-891 (CN-AML and MDS patients) were sequenced by Sanger sequencing as previously described 5 and with primers listed in Supplementary Table S1 . Patient samples were also assessed for other frequently mutated genes in AML and MDS as previously described (see
Supplementary Methods).
6-9 All mutations were confirmed in an independent experiment. Sequence analysis was performed with the Mutation Surveyor software (Softgenetics, State College, PA, USA). The somatic or germline status of mutations in miR-142 was established by evaluating T-cells (CD3 + CD11b -CD14 -CD33 -) purified from diagnostic samples by flow cytometry when available (n=2).
Gene expression levels of miR-142-3p and miR-142-5p were assessed by real-time reverse-transcriptase-polymerase chain reaction (RT-PCR) as detailed in the supplement. Overall survival (OS), complete remission (CR) and relapse-free survival (RFS) were calculated as previously described. 10, 11 The statistical analyses were performed with the statistical software package SPSS 21.0 (IBM Corporation, Armonk, NY).
In the whole cohort, we identified seven patients with mutations in miRNAs (0.74%) ( Table 1 ). All mutations were heterozygous ( Figure S1 ). MiR-142-3p was the most 4 frequently affected miRNA with five patients showing a mutation (0.53%, Figure 1A and S1). The somatic origin could be confirmed for miR-142-3p by analyzing T-cells which did not show the mutation (n=2). All of these mutations affected the seed region of miR-142-3p, thereby potentially changing the target specificity of miR-142.
In line with this, target prediction for miR-142-3p with targetscan (release 5.2: June 2011, www.targetscan.org/vert_50/) showed 250 conserved targets, while three of four mutations had much fewer predicted targets (pos54U>C: 245 conserved targets, pos55A>G: 76, pos56G>U: 95, and pos57U>C: 4 conserved targets (see Supplementary Table S2) ). The overlap of the predicted target genes was 0 to 7.9% between wildtype and mutated miR-142-3p in these four positions, suggesting that mutations in miR-142 are loss-of-function mutations. Functional validation of the mutated miRNAs confirmed that mutations of miR-142-3p pos54U>C, pos56G>U, and pos57U>C had little or no effect on protein expression of miR-142-3p targets CCNT2 and MAP3K7IP2 (TAB2) 12 in leukemic and fibroblast cells in contrast to wildtype miR-142-3p, which knocked down protein expression ( Figure 1B and
Supplementary Figure S2 ). The partial knockdown of target genes by the mutation at pos55A>G can be explained by the wobble effect of guanosine.
Mutations in miR-142 occurred in male and female patients ( , we also evaluated the expression of miR-142-3p and miR- 
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Mutational analysis
The following genes were analysed for mutations in AML patients: FLT3-ITD, NPM1,
CEBPA, DNMT3A, TET2, IDH1, IDH2, MLL-PTD, WT1, NRAS, SETBP1, STAG1, STAG2, RAD21, SMC1A, SMC3, and the fusion genes CBFB/MYH11, RUNX1/RUNX1T1, MLL/MLLT3, NUP98/NSD1.
The following genes were analysed for mutations in MDS patients: ASXL1, DNMT3A,
IDH1, IDH2, RUNX1, NRAS, TP53, NPM1, SF3B1, SRSF2, U2AF1, ZRSR2,
SETBP1.
Gene expression analysis
Real-time reverse-transcriptase-polymerase chain reaction (RT-PCR) was performed with patient-derived RNA using RNU48 as an endogenous control (assay ID 4427975, Life Technologies, Darmstadt, Germany). MiR-142-3p and miR-142-5p expression levels were quantified using the TaqMan Gene Expression Assay (Life 
Construction of lentiviral vectors
The retroviral MDH1-miR-142-PGK-GFP vector was obtained from Addgene. To generate the lentiviral vector pdc-H1-miR-142-3p-SEW, the plasmid pdc-SEW (pdc:
plasmids resulting in double-copy proviruses) was digested with SnaBI and treated with bacterial alkaline phosphatase. The H1-miR-142-3p cassette was excised from MDH1-miR-142-PGK-GFP with EcoR//BamHI, the cohesive ends were filled in using 
